Bristol-Myers eyes California for immuno-oncology HQ; GSK faces new corruption front;

@FierceBiotech: We're looking for 2014's Fiercest women in biotech. More | Follow @FierceBiotech

@JohnCFierce: Good story. RT @JeanneWhalen: GSK is close to launching world's first malaria vaccine, but a rival is close behind. Story | Follow @JohnCFierce

@DamianFierce:  EU's CHMP recommends Novo's fixed dose combo of a GLP-1 and Victoza, to be marketed as Xultophy. More | Follow @DamianFierce

@EmilyMFierce: GlaxoSmithKline steps closer to making world's first malaria vaccine. Article | Follow @EmilyMFierce

> Bristol-Myers Squibb ($BMY) has sited a new stateside home for its immuno-oncology operations, signing a 10-year lease on a Redwood City, CA, research hub. News

> On top of its ongoing bribery woes in China, GlaxoSmithKline ($GSK) is facing allegations of corruption in Syria. Story

> Following an FDA approval earlier this week, Gilead Sciences' ($GILD) leukemia drug idelalisib (Zydelig) received a positive recommendation from a committee of European Medicines Agency advisers. Item

Medical Device News

@FierceMedDev: 3-D printing grows to scale within industry. Report | Follow @FierceMedDev

@StacyALawrence: Intuitive's surgical robot hit with another unfavorable study result. More | Follow @StacyALawrence

@VarunSaxena2: Boston Scientific hopes to capitalize on competitors' weaknesses. Story | Follow @VarunSaxena2

@MichaelGFierce: Most absorbent material on Earth gives poorly soluble drugs a boost. Article from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Fewer than half of American children are vaccinated against HPV, according to new estimates from the CDC. Story via The Atlantic | Follow @EmilyWFierce

> Covidien is popping the bubbly for positive Q3 numbers. More

> Varian, AngioDynamics fall on earnings disappointments. Story

> St. Jude laying off up to 270 workers in California. News

Pharma News

@FiercePharma: Top-read on FierceVaccines Thursday: $GSK submits world's first malaria vaccine for EMA approval. Story | Follow @FiercePharma

@TracyStaton: CVS Caremark lays out case for new specialty-drug pricing approach in JAMA editorial. Abstract via JAMA | Follow @TracyStaton

@EricPFierce: Merck KGaA's second largest manufacturing plant is going up in China to make diabetes drugs. Article | Follow @EricPFierce

@CarlyHFierce: Love this headline via @BloombergNews: "Wall Street Junk Euphoria Backs Ackman's Allergan Dreams." Story via Bloomberg. | Follow @CarlyHFierce

> J&J builds 9-month supply of Doxil with creative problem solving. Article

> Still reeling from China bribery probe, GSK faces corruption scandal in Syria. Story

> With Shire deal in the bag, Humira leap helps AbbVie hold its own. More

> Gilead's Zydelig, J&J's Imbruvica will go toe-to-toe in EU with nod for CLL. News

Suggested Articles

A new, late-phase analysis of the cholesterol-lowering inclisiran showed that it was able to cut LDL levels by 51% after nearly a year-and-a-half.

The data was highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.